Early Successes in an Open Access, Provincially Funded Hepatitis C Treatment Program in Prince Edward Island
Overview
Authors
Affiliations
Introduction: The availability of curative hepatitis C therapies has created an opportunity to improve delivery and access. Local providers, government, industry, and community groups in Prince Edward Island developed an innovative province-wide care model. Our goal was to describe the first year of program implementation.
Material And Methods: Using a community based prospective observational study design, all chronic hepatitis C referrals received from April 2015 to April 2016 were recorded in a database. Primary analysis assessed the time from referral to assessment/treatment, as well as the number of referrals, assessments, and treatment initiations. Secondary objectives included: 1) Treatment effectiveness using intention-to-treat analysis; and 2) Patient treatment experience assessed using demographics, adverse events, and medication adherence.
Results: During the study period 242 referrals were received, 123 patients were seen for intake assessments, and 93 initiated direct-acting antiviral therapy based on medical need. This is compared to 4 treatment initiations in the previous 2 years. The median time from assessment to treatment initiation was 3 weeks. Eighty-two of 84 (97.6%, 95% CI 91.7 - 99.7%) patients for whom outcome data were available achieved sustained virologic response at 12 weeks post-treatment; 1 was lost to follow-up and 1 died from an unrelated event. In the voluntary registry, 39.7% of patients reported missed treatment doses.
Conclusion: In conclusion, results from the first 12 months of this multi-phase hepatitis C elimination strategy demonstrate improved access to treatment, and high rates of safe engagement and cure for patients living with chronic hepatitis C genotype 1 infections.
Impact of voluntary testing on infectious disease epidemiology: A game theoretic approach.
Pepiot A, Supervie V, Breban R PLoS One. 2023; 18(11):e0293968.
PMID: 37934734 PMC: 10629633. DOI: 10.1371/journal.pone.0293968.
Province-to-province variability in hepatitis C testing, care, and treatment across Canada.
Mandel E, Underwood K, Masterman C, Kozak R, Dale C, Hassall M Can Liver J. 2023; 6(2):234-248.
PMID: 37503520 PMC: 10370727. DOI: 10.3138/canlivj-2022-0029.
Hepatitis C models of care: approaches to elimination.
Biondi M, Feld J Can Liver J. 2022; 3(2):165-176.
PMID: 35991853 PMC: 9202783. DOI: 10.3138/canlivj.2019-0002.
Li J, Casey J, Greenwald Z, Yasseen Iii A, Dickie M, Feld J Can Liver J. 2022; 4(1):59-71.
PMID: 35991475 PMC: 9203168. DOI: 10.3138/canlivj-2020-0026.
Byrne C, Beer L, Inglis S, Robinson E, Radley A, Goldberg D Aliment Pharmacol Ther. 2021; 55(5):568-579.
PMID: 34877667 PMC: 9300005. DOI: 10.1111/apt.16728.